Evidence map›Paper›PMID 37481633›Full record

ArticleMolecular diversity2024

In vitro trypanocidal activities and structure-activity relationships of ciprofloxacin analogs.

Helena D Janse van Rensburg, Keisuke Suganuma, David D N'Da

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Helena D Janse van RensburgCentre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, 2520, South Africa.ORCID http://orcid.org/0000-0001-5181-9428
Keisuke SuganumaNational Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Inada, Obihiro, Hokkaido, 080-8555, Japan. k.suganuma@obihiro.ac.jp.ORCID http://orcid.org/0000-0001-5809-8811
David D N'DaCentre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, 2520, South Africa.ORCID http://orcid.org/0000-0002-2327-0551

Funding

Japan Society for the Promotion of Science 148781Japan Society for the Promotion of Science 16K18793
6 · The paper itself

Abstract

Tropical diseases, such as African trypanosomiasis, by their nature and prevalence lack the necessary urgency regarding drug development, despite the increasing need for novel, structurally diverse antitrypanosomal drugs, using different mechanisms of action that would improve drug efficacy and safety. Traditionally antibacterial agents, the fluoroquinolones, reportedly possess in vitro trypanocidal activities against Trypanosoma brucei organisms. During our research, the fluroquinolone, ciprofloxacin (1), and its analogs (2-24) were tested against bloodstream forms of T. brucei brucei, T. b. gambiense, T. b. rhodesiense, T. evansi, T. equiperdum, and T. congolense and Madin-Darby bovine kidney cells (cytotoxicity). Ciprofloxacin [CPX (1)] demonstrated selective trypanocidal activity against T. congolense (IC

Indexed as

CiprofloxacinTrypanocidal AgentsAnimalsCattleCell LineStructure-Activity RelationshipTrypanosomaCiprofloxacinTrypanocidal Agents1,2,3-TriazoleAfrican trypanosomesCiprofloxacinTrypanocidal activity

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.